Objective: To specifically compare how DCE-MRI, MG, and U/S To find out which of the machines determine the accurate size of the tumor for patients receiving neoadju- vant treatment for breast cancer. Methods: This study used retrospective reports Forty-four Patient women diagnosed breast cancer from King Fahad Medical City in Radiology Department at Riyadh from October to December 2021 to assess the use of an advanced Dynamic contrast- enhanced magnetic resonance imaging system (DCE-MRI system), mammogram (MG), and ultrasound (US), and to confirm whether they accuracy and integration one another in breast cancer size analysis. Results: The results showed no significant difference in the tumor size according to the radio- graphic system of each case pre-chemotherapy, where the mean size of the tumor was 9.95, 8.64, and 11.17 cm2 through the MG, US, and MRI techniques, respec- tively. Also, the statistical treatment of data showed the P-value associated with the f-test was Greater than 0.05. In addition, the results showed there is no significant difference in the tumor size according to the radiographic system of each case post- chemotherapy. Conclusion: After analysis 44 reports of different women diagnosed with breast cancer and scanned using DCE-MRI, MG, and U/S. DCE-MRI’s predictive response evaluation can be used to determine the efficacy of chemotherapy in the early assessment stage.